News Search Results
Feb 25, 2026, 12:25 ET HYDRINITY Accelerated Skin Science Announces Breakthrough Clinical Results Demonstrating the First "Hydrating Retinoid" with Zero Reported Irritation
integrity, establishing a new class of performance-driven skincare."This study marks an important milestone in the HYDRINITY mission to fuse biotechnology with advanced skincare," said Keith O'Briant, CEO of HYDRINITY. "To have our research published in the Journal of Cosmetic Dermatology underscores
More news about: HYDRINITY Accelerated Skin Science
Feb 25, 2026, 11:00 ET Dental Burs Market to Reach US$ 1,232.3 Million by 2033 on Growth of Dental Procedures and Technological Innovation
(Research Application, Drug Discovery, Disease Diagnostics, Other Applications), End Use (Research and Academic Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others), and Regional Analysis for 2025-2032.
More news about: Persistence Market Research Pvt. Ltd.
Feb 25, 2026, 10:45 ET Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prevalence of dry age related macular degeneration among elderly populations. For instance, according to 2021 report by the National Center of Biotechnology Information (NCBI), it was estimated that about 90% of the population in the world suffer from dry age related macular degeneration.The
More news about: Allied Market Research
Feb 25, 2026, 09:40 ET Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 /PRNewswire/ -- Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the first patient has been dosed in its Phase 1/2 UNITE
More news about: MAHZI Therapeutics
Feb 25, 2026, 09:05 ET Tether Invests in Whop, World's Largest Internet Market, to Power Stablecoin Payments for the Next Generation of the Internet Economy
infrastructure, and real-world utility intersect.Its portfolio includes investments in artificial intelligence, financial services, energy, biotechnology, education, and digital media, as well as strategic stakes in industries such as commodities, remittances, and sports and entertainment. Tether
More news about: Whop
Feb 25, 2026, 09:05 ET Tether Invests in Whop, World's Largest Internet Market, to Power Stablecoin Payments for the Next Generation of the Internet Economy
infrastructure, and real-world utility intersect.Its portfolio includes investments in artificial intelligence, financial services, energy, biotechnology, education, and digital media, as well as strategic stakes in industries such as commodities, remittances, and sports and entertainment. Tether
More news about: Whop
Feb 25, 2026, 09:00 ET Foundation Fighting Blindness to Host Free Webinar on Regenerative Medicine Advances for Retinal Diseases
Research in Vision and Ophthalmology (ARVO).Jeff Stern, PhD, MD, is founder and chief medical officer of Luxa Biotechnology, where he is developing dry AMD treatment using RPE cell therapies. A retinal specialist with a PhD in biophysics and an MD in ophthalmology, Dr.
More news about: Foundation Fighting Blindness
Feb 25, 2026, 08:30 ET Halozyme to Participate in Upcoming Investor Conferences
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 25, 2026, 08:07 ET P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments
pathway from early diagnosis to accelerated orphan therapy development.Supported by a world-class consortium of leading biopharma companies, biotechnology innovators, patient advocacy groups, and globally recognized academic and clinical institutions, BeginNGS further strengthens P4ML's position as
More news about: Orphan Therapeutics Accelerator
Feb 25, 2026, 08:00 ET Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151
increasingly competitive DPP1 inhibitor landscape."About Melodia Therapeutics AGMelodia Therapeutics AG is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing innovative therapies targeting neutrophil-driven inflammatory diseases.About
More news about: Melodia Therapeutics AG
Feb 25, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Announces Appointment of Bob Purcell as Chief Communications Officer
announced the appointment of Bob Purcell as Chief Communications Officer. With 25 years of experience in corporate and product communications for biotechnology, pharmaceuticals, diagnostics, and healthcare technology companies, Purcell will support PICI's efforts to drive innovation and collaboration in
More news about: Parker Institute for Cancer Immunotherapy
Feb 25, 2026, 08:00 ET Evogene Releases CEO Letter to Shareholders
operate across the full range of collaboration models.In human health, we are advancing multiple partnered drug discovery programs with biotechnology companies and academic institutions. Throughout 2025 and early 2026, ChemPass AI™ discovered development-candidate predictions that have progressed
More news about: Evogene
Feb 25, 2026, 07:05 ET REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Feb 25, 2026, 03:00 ET ARTHEx Biotech Announces Publication in The American Journal of Human Genetics Highlighting the Discovery and Preliminary Preclinical Profile of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
VALENCIA, Spain, Feb. 25, 2026 /PRNewswire/ -- Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the publication of a peer-reviewed research article entitled
More news about: ARTHEx Biotech
Feb 24, 2026, 18:52 ET QURE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages QURE Investors with Losses to Contact the Firm
with an attorney.UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate
More news about: Kessler Topaz Meltzer & Check, LLP
Feb 24, 2026, 18:00 ET Nektar Therapeutics to Participate in Two Investor Conferences in March
conferences, please reach out to your respective representative.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 24, 2026, 16:01 ET AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Feb 24, 2026, 13:09 ET Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals
Feb 24, 2026, 10:08 ET Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing
continuity."The collaboration will support a broad range of applications, including investigational cell therapies and platform technologies across biotechnology, pharmaceutical, and government-sponsored programs. Both companies will continue operating independently while collaborating to support shared clients.About
More news about: Cellipont Bioservices
Feb 24, 2026, 10:00 ET Particles for Humanity Announces Publication Demonstrating Breakthrough in Vitamin A Stability for Food Fortification
CAMBRIDGE, Mass., Feb. 24, 2026 /PRNewswire/ -- Particles for Humanity, a mission-driven biotechnology company developing nutrition technologies for low- and middle-income countries, today announced the publication of new data in
More news about: Particles for Humanity
Feb 24, 2026, 10:00 ET Bloom Science Initiates Phase 1b Obesity Trial of BL-001, Advancing a Differentiated Approach Beyond GLP-1
patients, the ketogenic diet can be challenging to maintain long term.About Bloom ScienceBloom Science is a clinical-stage biotechnology company developing new therapies for neurological disorders and metabolic diseases, including obesity. Rooted in gut-brain axis biology and microbiome
More news about: Bloom Science, Inc.
Feb 24, 2026, 09:35 ET Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
https://www.financialnewsmedia.com/news-help/Latest Biotech Drugs Attracting Interest may also include:Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,
More news about: Market News Updates
Feb 24, 2026, 09:00 ET Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the appointment of Blake Arnold, CFA, as Chief Business
More news about: Kenai Therapeutics/BIOCOM
Feb 24, 2026, 09:00 ET BioMarin to Participate in Four Upcoming Investor Conferences in March
Company's website for a limited time following the conferences.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 24, 2026, 09:00 ET Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market
care, orthobiologics, and regenerative medicine, is pleased to announce a transformative investment and strategic partnership with Jellagen Ltd, the UK-based biotechnology innovator pioneering Collagen Type Zero: a next-generation, jellyfish-derived, sustainable biomaterial.
More news about: Royal Biologics